Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2025)

Historic Gross Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 93.0%.

  • Tarsus Pharmaceuticals' Gross Margin fell 2600.0% to 93.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.26%, marking a year-over-year increase of 2900.0%. This contributed to the annual value of 92.99% for FY2024, which is 21200.0% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Gross Margin of 93.0% as of Q3 2025, which was down 2600.0% from 93.92% recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Gross Margin's 5-year high stood at 107.1% during Q4 2021, with a 5-year trough of 79.85% in Q3 2023.
  • Moreover, its 5-year median value for Gross Margin was 93.92% (2025), whereas its average is 94.38%.
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -111000bps in 2022, then soared by 134100bps in 2024.
  • Over the past 5 years, Tarsus Pharmaceuticals' Gross Margin (Quarter) stood at 107.1% in 2021, then decreased by -10bps to 96.0% in 2022, then fell by -6bps to 90.7% in 2023, then rose by 2bps to 92.58% in 2024, then increased by 0bps to 93.0% in 2025.
  • Its last three reported values are 93.0% in Q3 2025, 93.92% for Q2 2025, and 93.35% during Q1 2025.